Search company, investor...

Stage

Other Investors | Alive

About Albea Pharmaceuticals

Through a series of acquisitions, Albea Pharmaceuticals intends to build a rapidly growing, profitable, and pan-European pharmaceutical company with a portfolio of marketed products, a direct sales and marketing organization in the major European countries (UK, Germany, France, Italy and Spain), and a pipeline of products in various stages of clinical development.'

Headquarters Location

Switzerland

Loading...

Loading...

Albea Pharmaceuticals Frequently Asked Questions (FAQ)

  • What is Albea Pharmaceuticals's latest funding round?

    Albea Pharmaceuticals's latest funding round is Other Investors.

  • Who are the investors of Albea Pharmaceuticals?

    Investors of Albea Pharmaceuticals include EW Healthcare Partners.

  • Who are Albea Pharmaceuticals's competitors?

    Competitors of Albea Pharmaceuticals include EUSA Pharma, Intas Pharmaceuticals, InClinica, Oceana Therapeutics, NovaMed and 7 more.

Loading...

Compare Albea Pharmaceuticals to Competitors

CSEM Logo
CSEM

CSEM, the Swiss Center for Electronics and Microtechnology, is a research and development company active in applied research, product development, prototype and low-volume production, and technology consulting. Its main fields of activity are micro- and nanotechnologies, microelectronics, systems engineering, microrobotics, photonics, information and communication technologies.

R
Resolvyx Pharmaceuticals

Resolvyx Pharmaceuticals offers CombinatoRx which is creating new combination medicines that attack disease on multiple fronts

I
INDENA SPA

Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

S
SpePharm Holding

A European specialty pharmaceutical company dedicated to hospital and specialist drugs.SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market.

P
P2D Biosciences

P2D, Inc. is a pharmaceutical company focused on developing new pharmaceuticals for brain disorders

S
Supercritical Fluid Technologies

Supercritical Fluid Technologies develops solutions for demanding separation and material processing needs. SFT provides equipment and custom solutions to meet specific needs in supercritical fluid extraction, reaction chemistry and high pressure applications.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.